Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | SDCBP | O00560 | 4/20 | 0.46 |
| ▸ | SDC2 | P34741 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.43 |
| ▸ | CSGALNACT1 | Q8TDX6 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2178532 | 1.00 | LMNA (0.60) | LMNATP53SDCBPSDC2RAB9A | |
| SCHEMBL2179942 | 0.92 | LMNA (0.58) | LMNATP53SDCBPSDC2SMN1; SMN2 | |
| SCHEMBL2179936 | 0.92 | LMNA (0.58) | LMNATP53SDCBPSDC2SMN1; SMN2 | |
| SCHEMBL2177691 | 0.92 | LMNA (0.60) | LMNATP53SDCBPSDC2RAB9A | |
| SCHEMBL2177698 | 0.92 | LMNA (0.60) | LMNATP53SDCBPSDC2RAB9A | |
| SCHEMBL2179988 | 0.92 | DGAT1 (0.53) | LMNATP53SDCBPSDC2RAB9A | |
| SCHEMBL2181456 | 0.92 | DGAT1 (0.53) | LMNATP53SDCBPSDC2RAB9A | |
| SCHEMBL2180318 | 0.92 | TP53 (0.57) | LMNATP53SDCBPSDC2RAB9A | |
| SCHEMBL2181127 | 0.92 | TP53 (0.57) | LMNATP53SDCBPSDC2RAB9A | |
| SCHEMBL2179718 | 0.90 | LMNA (0.51) | LMNATP53SDCBPSDC2DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748426-B2 | Inhibitors of diacylglycerol acyl transferase | Piramal Enterprises Limited (IN) | 2014-06-10 | — | — | US | claimed |
| US-20120289505-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Enterprises Limited (IN) | 2012-11-15 | — | — | US | claimed |
| EP-2519500-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Healthcare Ltd. (IN) | 2012-11-07 | — | — | EP | claimed |
| WO-2011080718-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-07-07 | — | — | WO | claimed |
| US-8748426-B2 | Inhibitors of diacylglycerol acyl transferase | Piramal Enterprises Limited (IN) | 2014-06-10 | — | — | US | disclosed |
| US-20120289505-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Enterprises Limited (IN) | 2012-11-15 | — | — | US | disclosed |
| EP-2519500-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Healthcare Ltd. (IN) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011080718-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289505-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | DGAT1, DGAT2, LCAT | LMNA 2193/4885TP53 2093/4885SDCBP 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.